Home » News » Industry news » Methylated cyclodextrin effectively prevents the crystallization of supersaturated drugs

Methylated cyclodextrin effectively prevents the crystallization of supersaturated drugs

Views: 0     Author: Chiba University     Publish Time: 2023-08-10      Origin: Site

Methylated cyclodextrin effectively prevents the crystallization of supersaturated drugs

by Chiba University

Methylated cyclodextrin effectively prevents the crystallization of supersaturated drugsSchematic illustration of inclusion complexation and crystallization inhibition abilities of cyclodextrins (CDs) on the model drugs: carvedilol (CVD) and chlorthalidone (CLT). Credit: Kunikazu Moribe from Chiba University, Japan

In the medicine market, most newly introduced drugs and drug candidates show poor water solubility, which prevents their absorption in the body. This, in turn, limits their therapeutic efficiency. Solubilizing agents such as cyclodextrins (CDs) are commonly employed to enhance their solubility.

CDs have a cyclic structure featuring a hydrophilic exterior and a hydrophobic cavity inside that can enclose to form inclusion complexes. However, solubilization does not necessarily enhance adsorption in the body, since the solubilized drugs cannot readily pass through biological membranes.

One way to improve the permeability of drugs through is by increasing their concentration in the solution to form a supersaturated state. However, supersaturated states are unstable as the drug tends to precipitate and form crystals, limiting its effectiveness.

To prevent this, the addition of effective crystallization inhibitors is necessary to stabilize drug supersaturation over a long period. CD derivatives are particularly advantageous as they can solubilize drugs as well as inhibit their crystallization. However, the mechanism underlying their crystallization inhibition effect remains poorly understood.

In this light, a study led by researchers from Chiba University, Japan, recently investigated the impact of 12 different CD derivatives with varying hydrophobic cavity sizes on crystallization inhibition of two poorly water-soluble drugs—carvedilol (CVD) and chlorthalidone (CLT).

Their work was published in the International Journal of Pharmaceutics. It involved contributions from Professor Kunikazu Moribe, Associate Professor Kenjirou Higashi, and Assistant Professor Keisuke Ueda.

"Different solubilization abilities of CD derivatives lead to different drug supersaturation levels, resulting in a misestimation of their crystallization inhibition strength. Thus, a systematic analysis of the drug crystallization inhibition effect while considering the solubilization effect of CD derivatives is essential," explains lead author Mengyao Liu, a Ph.D. student at the Laboratory of Pharmaceutical Technology at the Graduate School of Pharmaceutical Sciences at Chiba University.

The researchers evaluated the solubilization and crystal inhibition effect of each CD derivative on the two drugs by performing phase solubility tests and measuring the crystallization induction time—the time taken for a supersaturated solution to form crystals. In a phase solubility test, they dissolved the drugs in CD derivative solutions of different concentrations and examined their solubility.

For measuring the crystallization induction time, the researchers added the drugs in drops to form supersaturated solutions and then analyzed their concentrations at different time intervals after removing the precipitated crystals.

The phase solubility tests revealed that the addition of β-CD and γ-CD derivatives improved the solubility of CVD. However, CLT's solubility was enhanced only by the β-CD derivative. "Notably, the degree of improvement depends on the ability to form stable inclusion complexes that, in turn, depends on the size fitness between the drug molecule and the CD cavity," explains Prof. Moribe.

However, there was no correlation between the solubilization effect of the different CD derivations and their crystallization inhibition abilities. Moreover, methylated CD derivatives were more effective than their unmethylated counterparts in maintaining the supersaturated state. The researchers attributed the crystallization inhibition ability of the methylated CD derivatives to their highly hydrophobic outer surfaces, which sterically hinder the nucleation and crystal growth processes, and thus maintain the supersaturated state.

"We have discovered a novel function of methylated CD derivatives as effective stabilizers for supersaturated drugs, an effect that is independent of their inclusion complex formation ability," says Prof. Moribe.

In conclusion, these findings shed light on the potential application of CD derivatives in drug-supersaturated formulations, which, in turn, could facilitate the clinical use of poorly water-soluble .

Rm 1955,Building 2,No.215,Lianhe North Rd.,Fengxian Dist.Shanghai 201417 China
About Us
Tocosynth is the Chinese dosmetic susidiary company of Tocopharm,who mainly R&D and manufacturing chemicals raw materials based in Shanghai,China.Our company was established in 2012.
Sign up for our newsletter to receive the latest news.

Copryright © 2023 Tocopharm(Shanghai) Co., Ltd. Technology by Leadong.Sitemap